 |
 |
 |
 |
Diabetic Complications
A growing body of scientific evidence from FibroGen and others
implicates CTGF as a central mediator of multiple pathologies
underlying common complications of diabetes including: diabetic
nephropathy, the leading cause of end-stage renal disease; diabetic
retinopathy, the leading cause of blindness and visual disability;
and cardiovascular disease, which accounts for some 65% of deaths
among people with diabetes in industrialized nations. FibroGen is
focused on the discovery and development of novel therapies designed
to block CTGF for the treatment of chronic diabetic complications.
FibroGen has initiated clinical testing of FG-3019, the
Company's lead anti-CTGF therapeutic candidate, in patients with
diabetic nephropathy. |
|
|
|
